Altre lingue Mind Medicine (MindMed) Inc.

Azioni

MNMD

CA60255C8850

Tempo reale stimato Cboe BZX Altri mercati azionari 15:53:38 24/06/2024			Variaz. 5gg	Var. 1 gen.
7,51 ^USD	+2,04%		+1,20%	+106,83%

20/06	Mind Medicine (MindMed) Inc annuncia un incontro costruttivo di fine fase 2 con la FDA statunitense per MM120 nel Disturbo d'Ansia Generalizzato (GAD)	CI
05/06	Aggiornamento settoriale: i titoli del settore sanitario sono stabili nel premercato di mercoledì	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	12:47
Mind Medicine Inc.(NasdaqGS:MNMD) added to S&P Pharmaceuticals Select Industry Index	24/06/2024
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	21/06
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)	20/06
Mind Medicine Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder	20/06
MindMed ICPR 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study	06/06
Sector Update: Health Care Stocks Steady Premarket Wednesday	05/06
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug	05/06
Top Premarket Decliners	05/06
MindMed to Participate in June Conferences	28/05
Mind Medicine (MindMed) Inc. - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting Show Growing Burden and Impact of Generalized Anxiety Disorder in the US	10/05
MindMed to Participate at May Investor Conferences	09/05
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US	09/05
Mind Medicine Inc. Announces the Departure of Schond Greenway as Chief Financial Officer	08/05
MindMed Reports First Quarter 2024 Financial Results and Business Updates	08/05
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States	06/05
MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder	04/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Mind Medicine (MindMed) Inc.

Azioni

MNMD

CA60255C8850

Altre lingue

Filtri